Show simple item record

dc.contributor.authorBujanda Fernández de Pierola, Luis ORCIDes
dc.contributor.authorHijona Muruamendiaraz, Elizabethes
dc.contributor.authorLarzabal, Mikeles
dc.contributor.authorBeraza, Martaes
dc.contributor.authorAldazabal, Pabloes
dc.contributor.authorGarcía Urkia, Nereaes
dc.contributor.authorSarasqueta, Cristinaes
dc.contributor.authorCosme Jiménez, Ángeles
dc.contributor.authorIrastorza, Belenes
dc.contributor.authorGonzález, Albertoes
dc.contributor.authorArenas Mirave, Juan Ignacioes
dc.date.accessioned2010-12-14T11:28:26Zes
dc.date.accessioned2011-03-29T04:50:42Z
dc.date.available2010-12-14T11:28:26Zes
dc.date.available2011-03-29T04:50:42Z
dc.date.issued2008-09-09es
dc.identifier.citationBMC Gastroenterology 8(40) : (2008)es
dc.identifier.issn1471-230Xes
dc.identifier.urihttp://hdl.handle.net/10810/2186es
dc.descriptionEs reproducción del documenteo publicado en http://dx.doi.org/10.1186/1471-230X-8-40es
dc.description.abstractBackground: The prevalence of nonalcoholic fatty liver disease (NAFLD) is high. NAFLD is linked to obesity, diabetes mellitus, and hypertriglyceridemia. Approximately 20% of patients with NAFLD will eventually develop cirrhosis. Our purpose was to investigate whether resveratrol decreased hepatic steatosis in an animal model of steatosis, and whether this therapeutic approach resulted in a decrease in tumor necrosis factor alpha (TNF-alpha) production, lipid peroxidation and oxidative stress. Methods: Male Wistar CRL: Wi (Han) (225 g) rats were randomized into three groups. A control group (n = 12) was given free access to regular dry rat chow for 4 weeks. The steatosis (n = 12) and resveratrol (n = 12) groups were given free access to feed (a high carbohydrate-fat free modified diet) and water 4 days per week, and fasted for the remaining 3 days for 4 weeks. Rats in the resveratrol group were given resveratrol 10 mg daily by the oral route. All rats were killed at 4 weeks and assessed for fatty infiltration and bacterial translocation. Levels of TNF-alpha in serum, hepatic malondialdehyde (MDA), oxidative stress (superoxide dismutase, glutathione peroxidase, catalase and nitric oxide synthase) and biochemical parameters were measured. Results: Fat deposition was decreased in the resveratrol group as compared to the steatosis group (Grade 1 vs Grade 3, P < 0.05). TNF-alpha and MDA levels were significantly increased in the steatosis group (TNF-alpha; 33.4 +/- 5.2 vs 26.24 +/- 3.47 pg/ml and MDA; 9.08 +/- 0.8 vs 3.17 +/- 1.45 mu M respectively, P < 0.05). This was accompanied by increased superoxide dismutase, glutathione peroxidase and catalase and decreased nitric oxide synthase in the liver of resveratrol group significantly (P < 0.05 vs steatosis group). Bacterial translocation was not found in any of the groups. Glucose levels were decreased in the group of rats given resveratrol (P < 0.05). Conclusion: Resveratrol decreased NAFLD severity in rats. This effect was mediated, at least in part, by TNF-alpha inhibition and antioxidant activities.es
dc.language.isoenges
dc.publisherBioMed Centrales
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.subjectinsulin resistance modeles
dc.subjecthepatic steatosises
dc.subjectoxidative stresses
dc.subjectsteatohepatitises
dc.titleResveratrol inhibits nonalcoholic fatty liver disease in ratses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder(c) 2008 Bujanda et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/2.0),which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.es
dc.departamentoesMedicinaes_ES
dc.departamentoeuMedikuntzaes_ES
dc.subject.categoriaGASTROENTEROLOGY AND HEPATOLOGY


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record